57 results
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
Vergütung bei Krankheit, Unfall, Tod
Sec. 8
Compensation in case of illness, accident, death
(1) Bei einer vorübergehenden Arbeitsunfähigkeit, die … is entitled to undiminished payment of the fixed salary pursuant to Sec. 5 para. 1 for the month of death and the following twelve months. If the Executive
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
for the calendar year 2023 is possible until June 30, 2024).
§ 8
Vergütung bei Krankheit, Unfall, Tod
Sec. 8
Compensation in case of illness,
accident, death … 6. August 2026, verlängert sich der in Satz 1 genannte Zwölf-Monats-Zeitraum entsprechend über den 6. August 2026 hinaus.
death and the following
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
the death of the relevant Participant.
§ 8
CHANGE OF CONTROL
For purposes of this § 8, “Change of Control” means the occurrence of any
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
the death of the relevant Participant.
§ 8
CHANGE OF CONTROL
For purposes of this § 8, “Change of Control” means the occurrence of any of the following
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
transferable except as provided in this § 7.
The PSUs are transferable only by will or applicable laws of descent upon the death of the relevant Participant
SC 14D9
EX-99
qj4j1 blq2k59aztl0
11 Apr 24
Tender offer solicitation
11:57am
SC 14D9
EX-99
sckcc7lt3
11 Apr 24
Tender offer solicitation
11:57am
6-K
EX-99.1
dha3lcnzql3vo
20 Mar 24
Current report (foreign)
4:12pm
SC14D9C
EX-99.3
eioqw345
13 Mar 24
Written communication relating to third party tender offer
5:22pm
6-K
EX-99.1
so1cyer63zt7 9wv0x
13 Mar 24
Current report (foreign)
4:08pm
S-8
EX-99.1
f4y0ih y77gzxzcyvlg
6 Mar 24
Registration of securities for employees
12:33pm
6-K
EX-99.3
6il8qcjoouh5 k9pkq
7 Feb 24
MorphoSys Enters into Business Combination Agreement to be
6:57am
6-K
EX-99.2
u94h6no y6
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
peluxh tjv2voqwun
2 Nov 23
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
9:20am
S-8 POS
EX-99.2
m3cm o7th
26 Oct 23
Registration of securities for employees (post-effective amendment)
12:41pm
6-K
EX-99.1
zvt1masrk424
11 May 23
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
1:12pm
S-8 POS
EX-99.2
9w6us vlplr13d4b
28 Apr 23
Registration of securities for employees (post-effective amendment)
1:14pm
6-K
EX-99.1
kr60j8 t4
17 Apr 23
Current report (foreign)
8:13am
6-K
EX-99.1
qp2loj
4 Apr 23
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
4:09pm
6-K
EX-99
1xy83h 6ykd63by5
12 Dec 22
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
6:14am